Malaria incidence in Myanmar 2005–2014: steady but fragile progress towards elimination by unknown
Mu et al. Malar J  (2016) 15:503 
DOI 10.1186/s12936-016-1567-0
RESEARCH
Malaria incidence in Myanmar 
2005–2014: steady but fragile progress 
towards elimination
Thet Thet Mu1, Aye Aye Sein1, Tint Tint Kyi2, Myo Min3, Ne Myo Aung4, Nicholas M. Anstey5, Myat Phone Kyaw6, 
Chit Soe7, Mar Mar Kyi4 and Josh Hanson4,5,8* 
Abstract 
Background: There has been an impressive recent reduction in the global incidence of malaria, but the develop-
ment of artemisinin resistance in the Greater Mekong Region threatens this progress. Increasing artemisinin resist-
ance is particularly important in Myanmar, as it is the country in the Greater Mekong Region with the greatest malaria 
burden. If malaria is to be eliminated in the region, it is essential to define the spatial and temporal epidemiology of 
the disease in Myanmar to inform control strategies optimally.
Results: Between the years 2005 and 2014 there was an 81.1 % decline in the reported annual incidence of malaria 
in Myanmar (1341.8 cases per 100,000 population to 253.3 cases per 100,000 population). In the same period, there 
was a 93.5 % decline in reported annual mortality from malaria (3.79 deaths per 100,000 population to 0.25 deaths per 
100,000 population) and a 87.2 % decline in the proportion of hospitalizations due to malaria (7.8 to 1.0 %). Chin State 
had the highest reported malaria incidence and mortality at the end of the study period, although socio-economic 
and geographical factors appear a more likely explanation for this finding than artemisinin resistance. The reduced 
malaria burden coincided with significant upscaling of disease control measures by the national government with 
support from international partners. These programmes included the training and deployment of over 40,000 com-
munity health care workers, the coverage of over 60 % of the at-risk population with insecticide-treated bed nets and 
significant efforts to improve access to artemesinin-based combination treatment. Beyond these malaria-specific 
programmes, increased general investment in the health sector, changing population demographics and deforesta-
tion are also likely to have contributed to the decline in malaria incidence seen over this time.
Conclusions: There has been a dramatic fall in the burden of malaria in Myanmar since 2005. However, with the rise 
of artemisinin resistance, continued political, financial and scientific commitment is required if the ambitious goal of 
malaria elimination in the country is to be realized.
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Background
There has been significant recent progress in the fight 
against malaria [1]. In Southeast Asia the annual number 
of malaria cases declined by almost 50 % between 2000 
and 2014 [1], and as a result there is now a plan in the 
Greater Mekong Region for elimination of Plasmodium 
falciparum by 2025 and for elimination of all malaria 
by 2030 [2]. However, while there have been impressive 
gains, major challenges remain and if the momentum of 
the last 15  years is to be maintained, sustained global, 
regional and local commitment is required. The Greater 
Mekong Region has many poor, vulnerable and geo-
graphically remote populations and it is these people who 
bear the greatest burden of disease [1, 3, 4]. The region 
also has the unique challenge of artemisinin resistance 
that threatens not only recent local gains, but which also 
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has the potential to reverse positive global trends if it 
spreads to the rest of the world [5–7].
Myanmar has the greatest malaria incidence in the 
Greater Mekong Region [1, 8] and its new government 
and poorly resourced public health system will have 
to overcome a variety of political, economic and logis-
tic challenges if malaria is to be eliminated [9]. Several 
interventions have already been implemented and these 
include the training and deployment of community 
health workers [10, 11], the provision of insecticide-
treated bed nets [12] and strategies to improve access 
to rapid diagnostic tests [13] and artemisinin-based 
combination therapy (ACT) [14]. There has also been a 
concerted effort to improve diagnosis and management 
of the disease in the private sector where the majority 
of malaria cases are managed [15]; here there has been 
a particular focus on the removal of poor quality ACT 
and artesunate monotherapy [14, 16]. While mathemati-
cal modelling has a valuable role to play in determining 
the efficacy of such interventions to decrease the malaria 
burden [17, 18], these models require detailed and reli-
able data so that decision-makers may target disease con-
trol programmes optimally.
The Health Management Information System (HMIS) 
section of the Department of Health in Myanmar pro-
duces a monthly report based on data collected in the 
field by health care workers in the country’s public health 
system. To document the changing epidemiology of clini-
cal malaria in Myanmar, the last ten years of available 
HMIS malaria data (2005–2014) were analysed to dem-
onstrate both the progress that has been made and the 
challenges that remain.
Methods
Data from between 1 January, 2005 and 31 December, 
2014 were collected from the HMIS database, which 
documents every reported case of malaria in the coun-
try’s public health system. Each case is notified to the 
local rural health centre that generates a report that is 
sent to the township health department. A township level 
report is then forwarded centrally to the HMIS and to 
the health department of each of Myanmar’s states and 
regions. From 2012, only patients with a diagnosis of 
malaria confirmed by microscopy or rapid diagnostic test 
were included as cases. Prior to 2012, limited access to 
definitive diagnostic testing in many areas of the coun-
try meant that ‘probable cases’ (based on clinical pres-
entation and disease course) were also included as cases. 
The HMIS database does not differentiate malaria cases 
by species. Hospital inpatient data are also collected 
monthly from all hospitals and this is forwarded to the 
HMIS; these data capture the principal diagnosis of every 
hospital admission in the country and includes the cause 
of all deaths.
Incidence calculations were based on official contem-
poraneous estimations of population size. No census was 
performed in Myanmar between 1982 and 2014 and so 
these official population data were based on the 1982 
census and official projected estimates of fertility, migra-
tion and mortality [19]. Data were collected in Microsoft 
Excel and Figures were constructed with Microsoft Excel 
and Map Window.
Ethics
The Chair of the Menzies School of Health Research 
Human Research Ethics Committee (HREC) deemed that 
the work could be exempted from the review of the full 
HREC as it posed negligible risk to participants.
Results
Disease incidence
Over the course of the study period, the reported national 
malaria incidence fell from 1341.8 cases per 100,000 pop-
ulation, to 253.3 cases per 100,000 population, a decline 
of 81.1 % (Fig. 1). The reported incidence fell in all of the 
states and regions of the country, ranging from a 61.8 % 
decline in the Ayeyarwaddy Region to a 94.4 % decline in 
Mon State (Fig. 2; Table 1).
Malaria mortality
Over the course of the study period, the reported national 
malaria mortality fell from 3.79 deaths per 100,000 popu-
lation, to 0.25 deaths per 100,000 population, a decline 
of 93.5 % (Fig. 3). The reported mortality fell in all of the 
states and regions of the country, ranging from a 77.3 % 
decline in Chin State to a 100  % decline in Kayah State 
(in the last 2  years of the study period there were no 
reported malaria deaths in Kayah State) (Fig. 4; Table 2).
Hospital admissions
In 2005, 7.8  % of all hospital admissions in Myanmar 
were due to malaria. This declined by 87 % to 1.0 % of all 
hospital admissions in 2014 (Fig. 5). These data were not 
broken down by state and region.
Discussion
There has been a marked recent decline in reported 
malaria incidence and mortality in Myanmar’s public 
health system. These national data, collected during a 
period of increased political and financial commitment 
to the rapid escalation of disease control programmes, 
echo the findings from smaller studies performed in dif-
ferent parts of the country during the same period [9, 
20–23].
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One of the key interventions in Myanmar has been 
the training and deployment of over 40,000 commu-
nity health workers who complement the care provided 
by health care workers in rural locations which bear the 
greatest burden of disease [1, 15]. Although the pro-
gramme has not been without its challenges [10], it is 
relatively inexpensive to implement [18] and allows a 
socio-economically disadvantaged population improved 
access to early and reliable diagnosis and treatment [24–
26]. While the primary role of these community health 
workers has been the care of patients with symptoms of 
malaria, they also potentially have a role to play in the 
implementation of other malaria control activities such 
as the distribution of insecticide-treated nets (ITNs) 
and  the coordination of indoor residual spraying (IRS) 
[14]. They might also contribute to the triage and man-
agement of other diseases, which could defray the costs 
of the programme [15, 27].
Myanmar commenced an ITN distribution programme 
in 2001. Presently there is coverage of over 60  % of the 
country’s at-risk population [1] and there are plans to 
improve this coverage to over 80 % of the at-risk popu-
lation [15]. While again this programme has its chal-
lenges [12], it is likely to have significantly contributed 
to the decline in cases in the country over the course of 
the study period [28, 29]. An advantage of the ITN pro-
gramme is its ability to access less developed and remote 
locations more effectively than other interventions [30]. 
Since 2010, there has been mass distribution of long-
lasting insecticide-treated nets which has focussed par-
ticularly on highly mobile migrant workers, a population 
that is more likely to be non-immune and vulnerable to 
malaria than local residents [12]. Although there is DDT 
and pyrethroid resistance in Myanmar [1], targeted use 
of IRS may also be appropriate in high-transmission set-
tings [14].
ACT has transformed the treatment of malaria, con-
tributing to the significant decline seen in malaria inci-
dence globally [29, 31] and it has almost certainly had 
a major positive impact in Myanmar. ACT has been 
recommended as the first-line treatment of malaria in 
the national malaria treatment policy since 2002 and 
this study period captures the rapid upscaling of pro-
grammes to improve access to ACT in both the public 
and private health sector. However, the recent rise of 
artemisinin resistance is perhaps the greatest current 
threat to this progress [5, 6]. Over a quarter of patients 
Fig. 1 National incidence (per 100,000 population) of malaria in 
Myanmar 2005–2014
Fig. 2 Geographical distribution of malaria cases 2005–2014 (expressed as incidence per 100,000 population)
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in southern Myanmar had a measurable parasitaemia 
72  h after initiating artesunate therapy [32]. While on 
the Thai–Myanmar border, there has been a decline in 
PCR-adjusted cure rates with the standard regimen 
of artesunate-mefloquine (MAS3) from 100  % in 2003 
to 81.1  % in 2013 [23]. In 2009 the Myanmar Malaria 
Technical and Strategy Group recommended that 
artemether–lumefantrine should be used as first-line 
therapy, however it can be anticipated that resistance 
will evolve to this combination in time as well [33, 34]. 
Table 1 Malaria incidence (per 100,000 population) by region/state 2005–2014
a Between 2005 and 2014
b Nay Pyi Taw was formed as an administrative region in 2010; until 2012 data were included in the Mandalay region
Region/state 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 % declinea
Ayeyarwaddy 437.8 382.1 436.6 352.6 301.1 483.1 585.5 361.3 298.3 167.4 61.8
Bago 854.9 821.9 704.9 1178.8 1108.3 980.6 784.6 484.5 246.6 68.6 92.0
Chin 6109.8 5499.2 5072.6 4811.0 5467.0 4615.4 4584.2 2613.6 1583.7 1499.6 75.5
Kachin 4375.4 4968.6 3806.2 3899.5 6259.0 7335.6 3804.9 2374.2 1691.6 832.2 81.0
Kayah 3197.0 3667.4 3504.0 3098.4 3272.8 3057.3 2799.6 1858.6 1068.2 517.1 83.8
Kayin 1702.7 1827.1 1484.4 1544.2 1562.4 1716.4 1472.9 970.0 869.4 435.2 74.4
Magway 738.9 650.3 758.6 808.6 873.1 1010.3 526.7 322.1 161.8 85.9 88.4
Mandalay 337.3 263.7 288.9 310.4 353.2 372.1 372.6 279.5 147.7 74.4 78.0
Mon 1147.6 1049.4 1172.7 1139.2 1161.6 1245.4 905.1 362.2 175.7 64.2 94.4
Nay Pyi Tawb n/a n/a n/a n/a n/a n/a n/a 250.3 147.8 91.7 n/a
Rakhine 6511.3 7811.4 5141.1 4135.5 3736.0 3727.7 2846.9 1752.8 877.8 628.1 90.4
Sagaing 1552.2 1383.7 1324.3 1564.9 1962.4 2313.3 1523.6 1085.6 755.1 536.0 65.5
Shan 1629.4 1619.3 1376.9 1474.2 1452.2 1421.4 1095.5 799.9 588.7 365.2 77.6
Tanintharyi 2172.0 2713.0 2263.5 2391.9 2504.0 2888.6 3581.6 2166.9 1291.4 421.4 80.6
Yangon 122.7 124.7 96.3 104.8 91.1 76.4 38.3 25.4 12.0 8.6 93.0
National 1341.8 1415.4 1192.9 1226.5 1327.3 1420.0 1085.2 686.0 438.3 253.3 81.1
Fig. 3 National mortality rate (per 100,000 population) of malaria in Myanmar 2005–2014
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Dihydroartemisinin–piperaquine has been shown to be 
effective in Myanmar [35], but resistance has developed 
in other areas of Southeast Asia [36, 37] and would also 
be expected in Myanmar if rolled out on a larger scale 
[33]. Continued monitoring of the therapeutic efficacy 
of first- and second-line medicines with timely change 
of anti-malarial treatment policy is therefore essen-
tial. Future approaches may require additional novel 
strategies, including the use of longer ACT courses [38], 
sequential ACT courses [39] or the use of triple ACT 
(TACT), which combines partner drugs with different 
resistance mechanisms [39]. Mass drug administration 
has also been proposed [39, 40]. In the meantime it will 
be essential to ensure that ACT courses are completed 
[39], that primaquine is routinely used to sterilise game-
tocytes [36] and that these pharmacological approaches 
Fig. 4 Geographical distribution of malaria deaths 2005–2014 (expressed per 100,000 population)
Table 2 Malaria mortality (per 100,000 population) by region/state 2005–2014
a Between 2005 and 2014
b Nay Pyi Taw was formed as an administrative region in 2010; until 2012 data were included in the Mandalay region
Region/state 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 % declinea
Ayeyarwaddy 1.88 1.78 1.17 0.90 0.81 0.97 0.74 0.64 0.21 0.16 91.5
Bago 3.62 3.35 1.81 2.74 1.92 0.96 0.87 0.61 0.27 0.12 96.6
Chin 12.44 9.31 4.94 6.70 5.11 5.67 7.35 1.88 0.82 2.82 77.3
Kachin 19.17 21.02 12.23 8.64 15.98 7.68 5.06 3.81 2.58 0.34 98.2
Kayah 5.09 8.76 2.99 2.99 5.92 1.86 1.80 0.75 0.00 0.00 100.0
Kayin 5.32 7.09 2.11 3.55 2.16 3.65 2.30 1.44 2.18 0.48 91.0
Magway 2.16 2.28 1.70 1.66 1.02 0.54 0.24 0.15 0.22 0.07 96.6
Mandalay 1.60 1.26 0.99 1.09 1.12 0.95 0.56 0.09 0.14 0.21 87.1
Mon 3.10 2.23 2.31 2.29 1.97 1.86 1.23 0.56 0.41 0.05 98.5
Nay Pyi Tawb n/a n/a n/a n/a n/a n/a n/a 0.10 0.31 0.00 n/a
Rakhine 4.48 5.28 2.54 2.61 2.29 1.47 1.15 0.61 0.34 0.15 96.6
Sagaing 5.38 4.86 2.65 3.39 3.71 2.42 1.68 1.56 1.06 0.82 84.7
Shan 8.17 7.08 4.03 4.05 3.01 3.45 2.25 1.14 0.88 0.23 97.2
Tanintharyi 3.96 7.57 4.94 4.80 3.28 3.60 1.61 1.17 0.44 0.14 96.4
Yangon 0.60 1.28 0.70 0.52 0.46 0.36 0.08 0.00 0.02 0.02 97.4
National 3.79 3.86 2.27 2.37 2.24 1.73 1.17 0.73 0.50 0.25 93.5
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are complemented by more aggressive use of vector 
avoidance and control measures [29, 41].
It is interesting to note that four of the areas most 
affected by artemisinin resistance in the north and east 
of the country (namely Kachin State, Shan State, Kayah 
State, and Mon State) were the four regions with the 
greatest falls in mortality over the course of the study. 
A fifth state in the east of the country affected by arte-
misinin resistance, Kayin State, had a fall in mortality 
that was lower than the national decline, but which was 
still an impressive 91 %. This does not diminish the clini-
cal significance of the artemisinin resistance; it rather 
reflects an awareness of the issue and an extensive invest-
ment in malaria control programmes in these regions by 
the national government, donors, NGOs, and partners.
However, while the evolution of artemisinin resist-
ance has captured much of the world’s attention recently, 
other factors contribute to the persistence of the disease 
and malaria related deaths. Chin State in the northwest of 
the country was the region with the highest disease inci-
dence in 2014, the highest mortality in 2014 and the low-
est fall in mortality over the course of the study. This is 
despite the state having relatively low rates of artemisinin 
resistance compared to other regions in Myanmar [6]. 
The ongoing malaria transmission and relatively high 
malaria mortality in Chin State may be related less to 
artemisinin resistance than the fact that it is the poor-
est state in the country, with a dispersed population in a 
very mountainous region with few transportation links; 
all of which hamper the upscaling of effective public 
health interventions [42]. The Ayeyarwaddy Region had 
the smallest decline in malaria incidence over the course 
of the study. In May 2008, this region bore the greatest 
brunt of Cyclone Nargis, the largest natural disaster in 
Myanmar’s recorded history. The resulting damage to 
infrastructure and health systems may have contributed 
to the rise to pre-2005 incidence levels in the ensuing 
years, before the decline in incidence resumed in 2012.
The importance of factors beyond targeted malaria 
control programmes is underlined by the fact that the 
decline in malaria incidence in Myanmar began in the 
early 1990s, well before these malaria specific pro-
grammes were introduced. Greater government health 
spending, resulting in more health facilities and health 
care workers, has improved access to care [15]. Changing 
population demographics may also have contributed to 
Fig. 5 Percentage of all hospital admissions due to malaria 2005–2014
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the decline as there has been a significant increase in the 
number of people living in urban environments where 
malaria incidence is lower [43]. Meanwhile, the recent 
rate of deforestation in Myanmar has been amongst the 
highest in the region [44] and this is likely to have had an 
effect on vector populations [45].
However, the study has significant limitations and 
the data should be viewed with some caution. Primary 
health workers with little training in data management 
and limited access to electronic databases collected the 
majority of the data. It is therefore likely to be imperfect. 
In some locations, particularly early in the study period, 
access to reliable diagnostic testing was sub-optimal. 
It was only from 2012 that only laboratory-confirmed 
cases were recorded, although it should be noted that 
if only this 2012–2014 period is examined, the reported 
national malaria incidence declined by 63.1  %, and the 
reported national malaria-related mortality fell by 
65.8  %. HMIS data include only malaria cases that are 
managed in the public health system and as the majority 
of patients with malaria in Myanmar receive their care 
in the private health system, in which there is no formal 
data collecting system, it is almost certain that the abso-
lute incidence and mortality are higher than is reported 
here [15]. Determination of the population in each state 
and region was also problematic. The last national cen-
sus completed prior to the study period was in 1983 and 
during the study period the population was only  esti-
mated in each region of the country, even at an official 
level [19]. Indeed, the 2014 census led the national popu-
lation to be revised downwards from the government’s 
estimated figure of 60.98 million in 2012 to 51.49 mil-
lion [46]. This suggests again that the incidence data 
here are likely to be an underestimate. However, the fact 
that the population figures were determined in the same 
manner over the entire course of the study, which was 
the national standard at the time, means that the tem-
porospatial trends in the incidence data still offer valu-
able insights into the progress that has been made and 
the obstacles that remain.
There are other caveats. The HMIS data do not record 
the Plasmodium species causing malaria, which is 
important, as there are different challenges in eliminat-
ing P. falciparum and Plasmodium vivax. There was no 
formal quality assurance programme in place to con-
firm the reliability of the HMIS data, although this is 
planned in the future. Finally, while the fall in disease 
incidence and mortality coincided with the expansion of 
the aforementioned malaria-specific programmes, it was 
not possible to link this central HMIS data with local 
data on ACT prescription, ITN use and health-seeking 
behaviour. It is therefore not possible to state conclu-
sively that these malaria programmes are responsible for 
the progress seen, although given their efficacy in other 
parts of the world, this inference may not be unreason-
able [28, 29, 31].
While these data are positive, major challenges remain 
and there are many historical precedents for resurgence 
of malaria [47, 48]. It would be potentially catastrophic 
if artemisinin resistance travels from Southeast Asia to 
Africa, where there is a far greater burden of disease, and 
in many cases even more fragile public health infrastruc-
ture [1, 5]. For continued progress on a national level, it 
will be essential for there to be ongoing coordination and 
cooperation between the public sector, private sector 
and affected communities, particularly mobile popula-
tions [4]. At a regional level there needs to be expanded 
collaboration, technical support and information sharing 
[15].
Conclusion
The data presented here are relatively basic; to guide pol-
icy more reliably in the future, it will be important to col-
lect and analyse more detailed data prospectively and to 
link these data with the delivery of malaria control meas-
ures, the movement and health-seeking behaviour of 
affected populations and indices of drug resistance. It will 
be essential to have robust quality assurance mechanisms 
to ensure that the collected data are complete, timely and 
accurate. However, despite these issues, this study shows 
the enormous progress that has been made in a coun-
try recovering from over half a century of conflict. With 
continued political and financial commitment and health 
system strengthening, the goal of eliminating malaria 
from the Greater Mekong Region by 2030 may not be an 
impossible one.
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